PPD, Inc. is opening a new laboratory in Suzhou, China, to support China-based biotech companies and Western pharmaceutical companies managing China research studies. The 67,000-square-foot facility in the Suzhou New District, Jiangsu Province, is expected to be fully operational in 2021. The company anticipates adding approximately 350 positions as a result of the expansion.
Christopher Fikry, MD, executive vice president of PPD Laboratories said, “Adding Suzhou to our central labs in Shanghai and Singapore expands the scope of our global laboratory footprint to help our customers advance drug development for patients across the world, particularly at a time when so much of our focus is on supporting trials aimed at developing vaccines and treatments for COVID-19.”
In addition to the new lab in Suzhou, PPD Laboratories includes bioanalytical labs in Middleton, Wisconsin, and Richmond, Virginia; GMP (good manufacturing practices) labs in Athlone, Ireland, and Middleton; central labs in Shanghai, China, Brussels, Belgium, Highland Heights, Kentucky, and Singapore; biomarker labs in Highland Heights and Richmond; and a vaccine sciences lab in Richmond.
To read the full release, click here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.